ATXI - Avenue Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.19
+0.08 (+1.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.11
Open6.04
Bid6.07 x 1300
Ask6.12 x 1100
Day's Range6.00 - 6.19
52 Week Range2.08 - 7.98
Volume6,618
Avg. Volume18,578
Market Cap102.507M
Beta (3Y Monthly)-0.44
PE Ratio (TTM)N/A
EPS (TTM)-1.96
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Aug. 14, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

  • GlobeNewswire

    Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Ms. Garrett Ingram has been appointed to its Board of Directors. Ms. Ingram joined Cipla USA, Inc. (“Cipla”) in July 2019 as Chief Commercial Officer, Specialty Hospital Business, U.S. to lead the transformation of the current and future specialty branded platforms.

  • Benzinga

    3 Foolproof Strategies To Minimize Risk

    While I still attempted to build a cushion on Monday with a couple of bigger positions in Avenue Therapeutics Inc. (NASDAQ: ATXI) and Genocea Biosciences Inc. (NASDAQ: GNCA), I’ve gotten the sense that momentum is fading and I don’t want to fall back into a pattern of chasing momentum until I get walloped with a big red trade.

  • Benzinga

    Avenue Therapeutics Trades Higher After Phase 3 Success

    Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success. The study also includes a standard-of-care IV opioid as an active comparator: IV morphine 4 mg. In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine. “The strong safety and efficacy results from this second Phase 3 trial are consistent with those from the first Phase 3 trial in bunionectomy surgery and demonstrated the utility of IV tramadol in post-surgical pain management regardless of the surgery type,” said CEO Lucy Lu in a press release.

  • GlobeNewswire

    Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its second pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 24 hours (SPID24) compared to placebo in patients with postoperative pain following abdominoplasty surgery. In addition, the trial met all of its key secondary endpoints.

  • GlobeNewswire

    Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, May 13, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

  • GlobeNewswire

    Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors. “Tom’s breadth and depth of operational and commercial experience, which includes leadership in the acute care pharmaceutical business, will be a significant asset to Avenue,” said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman.

  • GlobeNewswire

    Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 12, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

  • GlobeNewswire

    Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

    NEW YORK, Feb. 11, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage.

  • Zacks Small Cap Research

    ATXI: How Much Are CVRs Worth?

    Avenue Therapeutics (ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide $35 million in capital for a one-third stake in the company. Following FDA approval and the desired label, InvaGen will complete its acquisition of the company for an estimated $13.92 per share plus contingent rights to payments related to revenue and profit levels.

  • GlobeNewswire

    Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI)

    Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit has been filed and it is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (ATXI) for possible breaches of fiduciary duty related to the sale of the company to InvaGen Pharmaceuticals, Inc. and Madison Pharmaceuticals, Inc. Under the terms of the proposed transaction, Avenue shareholders are only anticipated to receive $13.92 for each share of Avenue common stock owned.

  • GlobeNewswire

    Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that the first patient has been dosed in a pivotal Phase 3 clinical trial of IV tramadol for the management of moderate to moderately severe pain in patients following abdominoplasty surgery. This study not only compares the efficacy and safety of IV tramadol to placebo, but also compares the safety and tolerability of IV tramadol to an active comparator (IV morphine),” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer. The Phase 3, multicenter, randomized, double-blind, three-arm trial will evaluate the efficacy and safety of IV tramadol 50 mg versus placebo.

  • PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI

    NEW YORK , Dec. 12, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Zacks Small Cap Research

    ATXI: InvaGen Acquisition Spices Up Quarterly Report

    By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) released third quarter 2018 financial results and submitted their Form 10-Q to the SEC on November ...

  • GlobeNewswire

    Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 14, 2018 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of.

  • Zacks Small Cap Research

    ATXI: InvaGen Capital Raise & Acquisition

    Avenue Therapeutics (ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will acquire the remaining shares for up to $180 million, subject to FDA approval and other specific terms. 5.8 million new shares will be issued at $6 per share, providing sufficient capital to advance IV tramadol to the post-approval stage. Furthermore, if the FDA grants approval and certain milestones are met, shareholders will receive payment of an estimated $13.92 per share and be eligible for contingent post-transaction consideration based on sales and profit metrics.

  • GlobeNewswire

    InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

    MUMBAI, India & NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that it has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and regulatory approvals, and other closing conditions.